Last reviewed · How we verify

NCT05702827

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

Completed Phase 3 Last updated 22 November 2024
What this trial tests

Phase 3 trial testing Bupivacaine-Meloxicam in Stress Urinary Incontinence in 148 participants. Completed in 18 April 2024.

Timeline
23 January 2023
Primary endpoint
22 March 2024
18 April 2024

Quick facts

Lead sponsorTriHealth Inc.
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment148
Start date23 January 2023
Primary completion22 March 2024
Estimated completion18 April 2024
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

TriHealth Inc. — full company profile →

Who can join

18 and older, female only, with Stress Urinary Incontinence or Surgical Incision. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stress Urinary Incontinence

Currently open trials in the same condition.

Other TriHealth Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05702827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing